Bortezomib Therapeutic Effect is Associated with Expression of Fgfr3 in Multiple Myeloma Cells

Min Guan,Lijun Zhu,George Somlo,Alison Hughes,Bingsen Zhou,Yun Yen
2009-01-01
Anticancer Research
Abstract:The ectopically expressed and deregulated fibroblast growth factor receptor 3 (FGFR3) has been observed in similar to 20% of multiple myeloma (MM) patients. In this study, we investigated whether the therapeutic effect of bortezomib is associated with FGFR3 expression. Materials and Methods: Cell proliferation and apoptosis assays were performed in minimal FGFR3 expressing U266 cells and compared to U266 cells overexpressing FGFR3 wild-type (T-U266), or Y373C (Y-U266) or K650E (K-U266) mutant FGFR3. Results: Our results suggested cell survival decreases in a dose-dependent manner. Interestingly, expression of FGFR3 protein was similarly dose dependent on bortezomib. It is confirmed the bortezoinib-induced apoptotic death is correlated with FGFR3 expression. Furthermore, increased expression of p-STAT3, Mcl-1 and VEGF suggested that bortezomib resistance associated with Y373C mutation and wild-type FGFR3 may be partly mediated through p-STAT3 signaling. Conclusion: Our data indicates that Y373C mutation and wild-type FGFR3 may be associated with bortezomib-related treatment rest. stance in multiple myeloma.
What problem does this paper attempt to address?